Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nobuo Toda

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
Gastrointestinal Endoscopy|July 29, 2011
Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancerTsuyoshi Hamada, Hiroyuki Isayama, Yousuke Nakai, et al.
Gastrointestinal Endoscopy|August 6, 2013
Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trialRie Uchino, Hiroyuki Isayama, Takeshi Tsujino, et al.
Internal Medicine (Tokyo, Japan)|February 5, 2014
Incidence of malignancies in patients with IgG4-related diseaseKenji Hirano, Minoru Tada, Naoki Sasahira, et al.
Global Health & Medicine|September 19, 2022
No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapyMasaaki Korenaga, Kazumoto Murata, Namiki Izumi, et al.
Journal of Gastroenterology and Hepatology|November 21, 2017
Multicenter study of endoscopic preoperative biliary drainage for malignant hilar biliary obstruction: E-POD hilar studyYousuke Nakai, Ryuichi Yamamoto, Masato Matsuyama, et al.
The Lancet. Infectious Diseases|April 13, 2015
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trialMasashi Mizokami, Osamu Yokosuka, Tetsuo Takehara, et al.
Journal of Viral Hepatitis|September 9, 2014
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trialMasao Omata, Shuhei Nishiguchi, Yoshiyuki Ueno, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
Gastrointestinal Endoscopy|July 29, 2011
Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancerTsuyoshi Hamada, Hiroyuki Isayama, Yousuke Nakai, et al.
Gastrointestinal Endoscopy|August 6, 2013
Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trialRie Uchino, Hiroyuki Isayama, Takeshi Tsujino, et al.
Internal Medicine (Tokyo, Japan)|February 5, 2014
Incidence of malignancies in patients with IgG4-related diseaseKenji Hirano, Minoru Tada, Naoki Sasahira, et al.
Global Health & Medicine|September 19, 2022
No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapyMasaaki Korenaga, Kazumoto Murata, Namiki Izumi, et al.
Journal of Gastroenterology and Hepatology|November 21, 2017
Multicenter study of endoscopic preoperative biliary drainage for malignant hilar biliary obstruction: E-POD hilar studyYousuke Nakai, Ryuichi Yamamoto, Masato Matsuyama, et al.
The Lancet. Infectious Diseases|April 13, 2015
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trialMasashi Mizokami, Osamu Yokosuka, Tetsuo Takehara, et al.
Journal of Viral Hepatitis|September 9, 2014
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trialMasao Omata, Shuhei Nishiguchi, Yoshiyuki Ueno, et al.
Pageof 9